IQVIA Holdings Inc. $IQV Shares Newly Purchased by Private Advisory Group LLC

Private Advisory Group LLC purchased a new stake in IQVIA Holdings Inc. (NYSE:IQV – Free Report) in the 3rd quarter, according to its most recent disclosure with the SEC. The fund purchased 5,522 shares of the medical research company’s stock, valued at approximately $1,485,000.

Several other hedge funds have also made changes to their positions in IQV. BlackRock Inc. bought a new position in IQVIA during the 2nd quarter worth $2,811,292,000. Canada Pension Plan Investment Board acquired a new stake in IQVIA in the second quarter worth $240,911,000. Bank of America Corp DE acquired a new stake in IQVIA in the second quarter worth $235,551,000. Legal & General Group Plc bought a new stake in IQVIA in the 2nd quarter valued at about $211,342,000. Finally, Bank of New York Mellon Corp bought a new stake in IQVIA in the 2nd quarter valued at about $180,296,000. Institutional investors own 89.62% of the company’s stock.

Insider Buying and Selling at IQVIA

In related news, insider James G. Berkshire sold 2,668 shares of IQVIA stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $261.33, for a total transaction of $697,228.44. Following the completion of the sale, the insider owned 10,890 shares of the company’s stock, valued at approximately $2,845,883.70. This trade represents a 19.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Eric Sherbet sold 4,446 shares of the firm’s stock in a transaction dated Monday, November 9th. The stock was sold at an average price of $278.83, for a total value of $1,239,678.18. Following the sale, the insider directly owned 24,989 shares of the company’s stock, valued at $6,967,682.87. This trade represents a 15.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 1.70% of the stock is currently owned by company insiders.

IQVIA Trading Up 0.1%

NYSE IQV opened at $265.44 on Monday. The stock has a market cap of $43.74 billion, a price-to-earnings ratio of 32.25, a PEG ratio of 2.36 and a beta of 1.16. IQVIA Holdings Inc. has a twelve month low of $154.50 and a twelve month high of $284.50. The company has a debt-to-equity ratio of 2.18, a quick ratio of 0.83 and a current ratio of 0.83. The firm’s 50 day moving average price is $267.55 and its two-hundred day moving average price is $211.88.

IQVIA (NYSE:IQV – Get Free Report) last announced its quarterly earnings data on Tuesday, October 27th. The medical research company reported $3.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.26 by $0.08. The firm had revenue of $4.43 billion during the quarter, compared to the consensus estimate of $4.37 billion. IQVIA had a return on equity of 30.02% and a net margin of 8.05%. The business’s revenue for the quarter was up 8.0% on a year-over-year basis. During the same period in the prior year, the business earned $3.00 EPS. Equities analysts anticipate that IQVIA Holdings Inc. will post 11.53 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have commented on IQV. Rothschild & Co Redburn upped their target price on shares of IQVIA from $284.00 to $287.00 and gave the stock a “buy” rating in a research report on Wednesday, July 29th. Jefferies Financial Group raised their price target on shares of IQVIA from $220.00 to $290.00 and gave the company a “buy” rating in a research note on Wednesday, July 29th. William Blair raised IQVIA to a “strong-buy” rating in a report on Tuesday, July 28th. Weiss Ratings downgraded IQVIA from a “hold (c+)” rating to a “sell (d+)” rating in a research report on Wednesday, October 28th. Finally, BMO Capital Markets increased their price target on IQVIA from $270.00 to $305.00 in a research note on Monday, October 19th. Two analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $294.21.

Check Out Our Latest Report on IQVIA

IQVIA Profile

(Free Report)

IQVIA Holdings Inc. provides clinical research services, healthcare data and analytics, and technology solutions to pharmaceutical, biotechnology, medical-device, and other healthcare organizations. Its services support the development and commercialization of medicines and other healthcare products. The company’s offerings include clinical trial planning and management, real-world data and evidence, consulting, and software and technology platforms for life sciences research and commercial operations.

See Also

Institutional Ownership by Quarter for IQVIA (NYSE:IQV)

Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.